A Phase 1b, Randomized, Double-Blind, Placebo-Controlled

Project: Research project

Project Details

Description

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects with Cystic Fibrosis Homozygous for the F508del-CFTR mutation
StatusFinished
Effective start/end date1/15/131/15/15

Funding

  • NIVALIS THERAPEUTICS, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.